pends mainly on whether hospitalization is necessary and particularly on the duration of hospital stay [3] [4] [5] [6] . The length of stay is influenced by various factors, such as the resolution of infectious parameters, the appearance of complications, and the treatment of associated comorbidities [7] [8] [9] .
Clinical stability, defined as the resolution of infectious parameters, is key in the evaluation of CAP and is an essential determining factor in the length of hospital stay [10] . However, this topic is not completely understood. One of the reasons for this is the difficulty in establishing potentially related variables in a satis-factory and homogeneous way. With regard to this difficulty, Halm et al. [11] established a definition of stability for CAP that includes 5 components: temperature, heart and respiratory rates, systolic blood pressure, and oxygen saturation. They found a positive correlation between the initial severity of CAP, measured by pneumonia severity index (PSI, or the risk class of Fine et al. [12] ), and the number of days needed until stability was reached.
We hypothesized that, in addition to initial severity, other factors (such as initial antibiotic treatment received) and host characteristics (such as the presence of comorbidities) could be involved in the resolution of signs of infection. In fact, the response to treatment, the appearance of complications, and the exacerbation of concomitant diseases are factors reported to prolong hospitalization [7, 8] .
The study of the resolution of infectious parameters in patients with CAP until clinical stability is reached is necessary to better characterize the natural history of CAP, to better characterize the response to treatment, and, probably, to individualize the length of antibiotic treatment. Thus far, the ideal duration of antibiotic treatment has been unknown, but a good understanding of the factors that influence clinical stability can provide useful information. It has thus been proposed that patients with rapid resolution of infectious parameters can receive treatments with shorter durations.
Our objective was to study factors related to the patient, pneumonia, and treatment that could be independently related to clinical stability. With this purpose, a multicenter observational study was performed involving hospitalized patients with CAP, using a multivariate statistical approach to identify factors that could independently predict clinical stability.
PATIENTS AND METHODS
Design and study population. From October 2000 through April 2001, a multicenter, observational, prospective study was performed in 15 Spanish hospitals. The study cohort comprised adult patients who had been hospitalized with CAP. The inclusion criteria were a clinical diagnosis compatible with CAP, with у2 clinical symptoms and a new infiltrate visible on radiographs. Patients with a prior neoplasm who had not received immunosuppressive treatment within the previous 6 months and residents of nursing homes were also included. The following patients were excluded: patients admitted within the previous 15 days or who developed pneumonia after hospital admission; transplant recipients or patients with a neoplasm who had received immunosuppressive treatment; patients with leukopenia (leukocyte count, !1000 cells/mm 3 ) or neutropenia (neutrophil count, !500 cells/mm 3 ), except if these symptoms were attributable to pneumonia; and HIV-positive patients with a CD4 cell count of !100 cells/mm 3 . Clinical stability was defined, on the basis of an approach similar to that of Halm et al. [11] , as the condition for which the following threshold values were achieved for all parameters: temperature, р37.2ЊC; heart rate, р100 beats/min; respiratory rate, р24 breaths/min; systolic blood pressure, у90 mm Hg; and oxygen saturation of у90% or arterial oxygen partial pressure (Pao 2 ) of у60 mm Hg when the patient was not receiving supplemental oxygen. We considered patients who were receiving home oxygen therapy to be stabilized when the need for oxygen was the same as that before hospital admission. Early treatment failure was defined as clinical deterioration, with у1 of the following symptoms: hemodynamic instability, respiratory failure (oxygen saturation of !90% or Pao 2 of !60 mm Hg with a fraction of inspired oxygen [Fio 2 ] of 0.21) or breathing impairment needing mechanical ventilation, radiological progression, or the appearance of new metastatic infectious foci within 72 h after commencement of antibiotic treatment. Late treatment failure was considered to have occurred if these conditions appeared or if fever and clinical symptoms persisted or reappeared after 72 h of treatment.
Data collection. The following data were recorded: age, sex, smoking and alcohol use habits, drug use, comorbid disease (chronic obstructive pulmonary disease; cardiac, liver, or renal diseases; CNS or deglutition disorders; and neoplasm), prior antimicrobial treatment, nursing home residency, and employment status. Clinical symptoms, initial risk class [12] , analytical data, and radiographic findings were recorded, as published elsewhere [13] . Initial empirical treatment complied with the Spanish Sociedad Española de Quimioterapia-Sociedad Españ-ola de Neumologia y Cirugia Torácica (SEQ-SEPAR) guidelines [14] in the following cases: for hospitalized patients with CAP, third-generation cephalosporin or amoxicillin-clavulanic acid, with or without a macrolide, or monotherapy with fluoroquinolone; and for patients admitted to the intensive care unit (ICU), third-or fourth-generation cephalosporin with an intravenous macrolide (clarithromycin) or fluoroquinolone. Receipt of other antibiotic regimens was considered indicative of noncompliance.
Complications were classified as cardiac, respiratory (new respiratory failure, exacerbation of concomitant respiratory disease, or pleural effusion), renal, or digestive complications and shock. The need for ICU admission and deaths were also recorded.
Statistical analyses. The statistical analysis was performed using the SAS software package, version 8.2 (SAS Institute). Patients who died or who had an alternative diagnosis at the end of the study were excluded. Of those included ( ), n p 1145 1033 (90%) were used to obtain the Cox survival model, and the remaining 112 patients, randomly selected, were used to validate the model as a predictor. Descriptive statistics are presented as percentages or as the mean or median with interquartile range (IQR). Univariate statistical analysis of all of the categorical variables and the number of days needed to reach statistical stability was performed using the Kaplan-Meier method. Comparisons of survival curves for the different groups were made using the log-rank test. Patients were censored at the point of the last recorded value. All analyses used as the significance level.
The independent association between variables and time to reach clinical stability (dependent variable) was assessed by 2 multivariate Cox proportional hazard models. Hazard ratios (HRs) and 95% CIs for all significant predictor variables were calculated.
In the first Cox model, the characteristics of the patient, the manifestations of pneumonia, the initial severity of disease (measured by PSI score), and the initial prescribed antibiotic treatment were analyzed to identify predictor independent factors (recorded during the first 24 h) related to clinical stability. They were entered into the model as categorical variables. The PSI scores were categorized in 2 groups (I and II vs. III-V), and the initial antibiotic treatment was defined as either compliant or noncompliant with Spanish guidelines. The second Cox model used the same variables together with those that appeared during hospitalization, such as complications and treatment failure.
The validation of the predictive models was made with the 112 patients whose data had not been employed to build the model. The real values of clinical stability of these patients were contrasted with the values that were estimated through the use of the model. Bivariant graphs of the residues based on tricks of the model against the function of accumulated risk were made. Both variables underwent a logarithmic transformation to normalize the distribution of data.
RESULTS

Patient Characteristics
A total of 1424 patients were recruited for the study. Eighty patients (5.6%) who died and those with an alternative diagnosis were excluded from the analysis. The main demographic characteristics, comorbidities, and PSI scores of the remaining 1145 subjects are shown in Patient demographic characteristics and comorbidities. The median time to reach clinical stability was 4 days (IQR, 2-6 days). In table 2, the time needed to reach stability is shown according to the demographic characteristics and comorbidities. No significant differences in age, sex, or alcohol intake were found. Patients with chronic bronchitis or neoplasia reached stability 1 day later than did other patients. The probability of clinical stability on day 4 of hospitalization was 58.2% for patients with chronic bronchitis and 67.7% for those with- out it ( ); for patients with neoplasia, the probabilities P p .003 were 51.7% and 64.5%, respectively ( ). For the re-P p .009 maining comorbidities, differences in the time to achieve stability did not reach statistical significance.
Initial symptoms and severity. The probability of reaching stability on day 4 of hospitalization was 57.2% for patients with dyspnea versus 76.1% for those without dyspnea ( ). It P ! .001 was 43.3% for patients with confusion versus 65.5% for those without it ( ). P ! .0001 The duration of time needed to reach stability based on initial severity showed a clearer relationship. The probability of reaching clinical stability on day 4 of hospitalization was greater when the risk class was lower (76.9% for class II, 66% for class III, 54.5% for class IV, and 43.2% for class V;
). The P ! .0001 probability of reaching stability for patients with multilobed CAP was 52.1%, whereas it was 67.4% if the infiltrate involved р1 lobe ( ), and the probability was 51.8% if pleural P ! .0001 effusion was present, compared with 64.2% if pleural effusion was not present ( ). P ! .05 Pathogens. The probability of reaching stability on day 4 for patients with CAP due to M. pneumoniae was 88.9%, compared with 63.4% for patients with CAP that was not due to infection with this microorganism ( ). P ! .05 Antimicrobial treatment. Sixty-eight percent of patients treated with antibiotics before hospital admission reached clinical stability on day 4, compared with 61.5% of those who were not treated with antibiotics ( ). Adherence to the Span-P p .02 ish guidelines for initial antibiotic treatment (81.1% of patients) was associated with a fewer number of days to reach stability. The probability of reaching stability on day 4 of hospitalization in patients treated according to guidelines was 65.7%, compared with 54.4% for those who were treated with other antimicrobial regimens ( ). The median number of days P ! .01 until clinical stability was achieved, according to different initial antibiotic regimen, was as follows: patients who received a third-generation cephalosporin plus macrolide reached stability by day 4 (IQR, days 2-6), patients who received amoxicillinclavulanic acid plus macrolide reached stability by day 4 (IQR, days 3-7), patients who received fluoroquinolone reached stability by day 4 (IQR, days 2-6), and those who received other antimicrobial regimens reached stability by day 4 (IQR, days 3-7).
Therapeutic response and complications. The probability of reaching stability on day 4 of hospitalization for patients with therapeutic failure was 12.9%, compared with 69.7% for those who did not have treatment failure ( ) (table 3) . P ! .0001 All complications were associated with a longer time needed to reach stability. The probability of reaching stability on day 4 of hospitalization for patients with renal insufficiency was 40.2%, compared with 65.4% for those without renal insufficiency ( ); for cardiac insufficiency, it was 31%, com-P ! .0001 pared with 66.3% for absence of cardiac arrest ( ); for P ! .0001 exacerbation of respiratory illness, it was 49.4%, compared with 64.6% for lack of exacerbation of respiratory illness (P p ); for shock, it was 16%, compared with 64.6% for absence .0008 of shock ( ); and for empyema, it was 8%, compared P ! .0001 with 64.8% for lack of empyema ( ). In patients ad-P ! .0001 mitted to the ICU, the probability of reaching stability on day 4 was 11.5%, compared with 66.5% for those who did not need intensive care ( ). P ! .0001
Time to Stability: Multivariate Analysis
The results of the 2 final Cox regression models are shown in table 4 . In the first model, 6 independent variables were identified as significantly associated with clinical stability; 5 were associated with slower clinical stability (dyspnea, confusion, higher PSI, multilobed radiographic infiltrates, and pleural effusion), and the sixth, antibiotic treatment according to guidelines, was associated with earlier clinical stability.
When response to therapy and complications were entered into the second Cox proportional hazard model, some initial independent variables disappeared, whereas others were main-tained. This second model also selected response to treatment, complications of disease, and admission to ICU as independent variables associated with longer time to reach clinical stability.
For the validation of the 2 proportional models of risks, 2 bivariant graphs of the residues based on tricks of the model against the function of accumulated risk were made. We observed an approximately straight line with slope value of 1, which indicates a correct adjustment to the model.
DISCUSSION
The most relevant findings of our study are the following (1) the median time needed to reach clinical stability is 4 days; (2) the initial factor associated with earlier clinical stability is adherence to antibiotic treatment guidelines, and those associated with slower stability are dyspnea, multilobed involvement, confusion, initial severity of disease (as measured by PSI), and pleural effusion; and finally, (3) patients who had treatment failure, who had renal, heart, or respiratory insufficiency, or who were admitted to the ICU reached clinical stability later than did others.
We found that the average time to reach stability was 4 days using an approach similar to that of Halm et al. [11] . Of the 5 proposals made by Halm and colleagues to define clinical stability, we decided to use the one closest to our clinical practice. We have corroborated the findings of Halm et al. [11] , who demonstrated that the initial severity of pneumonia (as measured by PSI) correlated with the number of days it took to reach clinical stability. In their study, the median time to stability was 3 days-1 day less than in our study. This difference could be because of a couple of reasons: (1) we chose р37.2ЊC instead of р37.8ЊC as a determining factor of clinical stability, (2) our patients were older and more severely ill, with a higher percentage of cases with risk classes IV-V.
In our study, we found that the time to reach stability was independently influenced (that is, after we adjusted for initial severity of disease) by several other factors, both initially and during the evolution of pneumonia. Thus, more time was needed to reach stability when patients with CAP had dyspnea and confusion at the time of hospital admission. In fact, confusion is one of the variables included in the PSI [12] and is also 1 of the 4 variables used to calculate the CURB (confusion, urea level, respiratory rate, and blood pressure) index (derived from the British Thoracic Society rules [15, 16] ). Other initial factors, such as pleural effusion and multilobed CAP, were also associated with a delay in reaching stability.
Interestingly, the initial antibiotic treatment (if it was in accordance with the Spanish guidelines) was independently associated with a shorter time needed to reach clinical stability. In previous studies, adherence to guidelines was associated with better outcome [17] [18] [19] [20] and shorter length of stay [17, 18] . However, the potential influence of treatment guideline adherence on the stability of CAP has not been previously proven. This interesting and novel finding should reinforce the necessity of implementation of guidelines for the management of CAP. With regard to ventilator-associated pneumonia, Luna et al. [21] found that receipt of adequate initial antimicrobial treatment was associated with a faster resolution of infectious parameters [21] . Recently, Silber et al. [22] were not able to prove that there was a relationship between early administration of antimicrobial therapy and clinical stability.
Clinical stability was reached 1 day earlier in patients with CAP due to M. pneumoniae than in others. However, because of the limited number of patients for whom an etiological diagnosis was obtained, it was not possible to obtain more information with regard to other microorganisms.
When complications of CAP and failure of CAP treatment were included in the second multivariate model together with initial variables, we found that cardiac and respiratory complications, empyema, and admission to the ICU were associated with a delayed clinical stability. Obviously, inadequate response to treatment was also associated with longer time to reach stability. Chronic bronchitis was the only comorbid condition independently associated with a greater amount of time needed until stability was reached. In this second model, some initial variables (such as the presence of dyspnea, confusion, high PSI, and multilobed CAP) remained significantly associated with stability, whereas adherence to treatment guidelines and pleural effusion were left out. A possible explanation could be the appearance in the model of treatment failure, because the response to treatment is a more powerful variable (HR, 0.3). An adequate response to therapy facilitates stability and depends on several factors, including initial antibiotic treatment. In a previous study, we found lower rates of treatment failure in patients with CAP who were treated according to guidelines, especially among those who received fluoroquinolones, and we found a higher failure rate when the antibiotics used differed from those in recommended regimens [13] .
The results provided by both models in our study are complementary, because they both yield information in the 24 h after hospital admission, and they yield more definite information later, at 72 h after commencement of antibiotic treatment. In addition, the importance of clinical stability to decide whether to discharge a patient has prognostic implications, as Halm et al. [23] have proven.
The resolution of infectious parameters in reaching clinical stability is also relevant for decisions regarding sequential treatment and the total duration of antibiotic treatment of CAP. The latest American Thoracic Society guidelines recommend a duration of 7-10 days [24] , on the basis of the causal microorganism, initial severity, and the subsequent hospital course. The Infectious Diseases Society of America's guidelines [25] and Canadian guidelines [26] also noted that the duration of antibiotic therapy depends on the response to treatment and can be assessed on the basis of resolution of infectious parameters. In our study, most of the patients who would reach clinical stability by day 4 of hospitalization could be identified within 24 h after hospital admission-and they could be identified more accurately at 72 h after admission-after adjusting for initial severity. Although we used PSI in our study, our results might be similar with other prognostic scales, by taking into account that we found factors that were independently associated with clinical stability-that is, after we eliminated the effect of initial severity. Therefore, for similar initial severity, patients with an adequate response to treatment and no complications will reach stability earlier, and they would thus require a shorter duration of antibiotic therapy. The possibility that the duration of antibiotic treatment could be safely shortened would permit the reduction of risks of adverse side effects of antibiotics, improve therapeutic fulfillment, and reduce costs; however, this has to be confirmed in randomized clinical trials.
In conclusion, the number of days necessary for the infectious parameters in CAP to reach stability depends on the comorbid condition, on the characteristics of the pneumonia, and on the antibiotic treatment employed after adjusting for initial severity. During hospitalization, the factors related to a delay in reaching stability are a lack of antibiotic treatment response, complications, and the need of admission to the ICU. The identification of factors that are related to the number of days needed for each patient to reach stability is useful for the clinician in planning the sequential therapy, determining hospital discharge, and tailoring the antibiotic treatment.
